17-hydroxyprogesterone test

Key Takeaways

17-hydroxyprogesterone (17-OHP) is a hormone precursor in the adrenal cortex; elevated levels indicate 21-hydroxylase deficiency and congenital adrenal hyperplasia (CAH).

Specimen is serum collected during follicular phase in females; CPT code 83498 applies; methodology is LC/MS or HPLC-MS/MS.

Reference ranges vary by age, sex, and menstrual phase: follicular females 15-70 ng/dL, luteal 35-290 ng/dL, males 27-199 ng/dL.

Practice management software like Pabau keeps digital forms and client records in one place, streamlining test ordering and result documentation for CAH, PCOS, and adrenal disorder workups.

Download your free 17-hydroxyprogesterone test reference guide

The 17-hydroxyprogesterone test is a cornerstone diagnostic for endocrine conditions affecting reproductive health and adrenal function. This clinical reference guide provides practitioners with essential ordering, interpretation, and documentation information for one of the most frequently ordered hormone tests.

What is the 17-hydroxyprogesterone test?

The 17-hydroxyprogesterone (17-OHP) test measures serum levels of 17-hydroxyprogesterone, a hormone intermediate in the cortisol biosynthesis pathway. Produced by the adrenal cortex, this hormone precursor accumulates when the enzyme 21-hydroxylase is deficient or dysfunctional, making 17-OHP measurement the gold standard screening for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.

The 17-hydroxyprogesterone test is ordered to evaluate adrenal steroidogenesis, screen newborns for CAH, investigate hyperandrogenic symptoms in reproductive-age females, and assess suspected adrenal insufficiency in adults. It is not a standalone diagnostic but part of a broader hormone panel.

Clinical uses and indications for 17-hydroxyprogesterone testing

The 17-hydroxyprogesterone test serves multiple diagnostic roles across pediatric and adult medicine:

• Congenital adrenal hyperplasia (CAH) diagnosis and monitoring: Elevated 17-OHP is the diagnostic marker for 21-hydroxylase deficiency, the most common CAH form (>90% of cases). Serial testing monitors disease control during treatment.
• Newborn screening: Mandatory in all US states and many international jurisdictions; identifies neonates at risk for classic CAH presenting with adrenal crisis.
• Polycystic ovary syndrome (PCOS) evaluation: Elevated 17-OHP (non-classic CAH range) occurs in 20-30% of PCOS patients; exclusion of non-classic CAH is part of differential diagnosis.
• Hirsutism and hyperandrogenism workup: Elevated androgens with abnormal 17-OHP point to adrenal source rather than ovarian.
• Adrenal tumor suspicion: Severely elevated 17-OHP may indicate adrenal cortical neoplasm; imaging follows abnormal results.
• Adrenal insufficiency evaluation: Low 17-OHP in the context of low cortisol suggests primary adrenal failure.

Test methodology and specimen requirements

Modern 17-hydroxyprogesterone testing uses liquid chromatography tandem mass spectrometry (LC/MS or HPLC-MS/MS), which provides superior specificity and accuracy compared to immunoassay. Immunoassay can produce falsely elevated results in neonates due to cross-reactivity with other steroids. LC/MS avoids this pitfall.

Specimen type is serum, not plasma. Collection timing is critical for reproductive-age females. Early follicular phase, days 3-5 of the menstrual cycle, is the standard for comparing results to published reference intervals. Post-ovulation (luteal phase) collections show 3-5 fold higher 17-OHP due to the progesterone rise. If luteal-phase results come back, interpret them against luteal reference ranges, not follicular. Specimen stability is approximately 14 days refrigerated. Verify this with your specific laboratory.

CPT code and billing information

CPT code 83498 is the standard procedural code for 17-hydroxyprogesterone quantification. Reimbursement varies by payer and indication. Verify coverage with the patient’s insurance before ordering. Newborn screening tests are typically covered by state programs and not billed to insurance.

Reference ranges by age, sex, and menstrual phase

17-OHP reference ranges vary significantly by age, sex, and reproductive status. Results must be interpreted against age- and sex-matched reference intervals. Using the wrong range leads to misinterpretation.

Critical timing note for females: Menstrual cycle phase dramatically affects 17-OHP concentration. Follicular phase (days 3-5) values are lower. Luteal phase (7-10 days after ovulation) values can be 3-5 times higher due to corpus luteum progesterone synthesis. Always document collection date and menstrual cycle phase on requisition forms. Lab reference ranges account for these variations, so confirm your lab’s specific intervals.

Streamline your test ordering and result documentation

Pabau's digital forms and integrated client records keep hormone test requisitions, results, and clinical notes organized in one searchable system.

Book a demo

Interpreting test results

High 17-hydroxyprogesterone in females

Elevated 17-OHP in reproductive-age females indicates potential adrenal or ovarian dysfunction. Clinical interpretation depends on degree of elevation and concurrent symptoms.

• Classic CAH (17-OHP typically >1,000-2,000 ng/dL): Homozygous or compound heterozygous 21-hydroxylase deficiency; presents in infancy with virilization (females) or salt-wasting adrenal crisis (both sexes). Requires lifelong glucocorticoid and mineralocorticoid replacement.
• Non-classic CAH (17-OHP typically 150-400 ng/dL): Mild enzyme deficiency; adult presentation with hirsutism, irregular periods, infertility, or metabolic dysfunction. More common in PCOS phenotype populations.
• PCOS with adrenal hyperresponsiveness: 17-OHP in the 100-150 ng/dL range during follicular phase may indicate exaggerated adrenal androgen response to ACTH; often coexists with ovarian hyperandrogenism.
• Adrenal tumors: Markedly elevated 17-OHP (>500 ng/dL) with concurrent very high cortisol or DHEA-S suggests adrenal cortical neoplasm; imaging (CT/MRI) is indicated.

Low 17-hydroxyprogesterone in females

Low 17-OHP is less commonly clinically significant but may indicate adrenal insufficiency when concurrent with low cortisol and elevated ACTH. Postmenopausal females naturally have lower 17-OHP due to decreased ovarian and adrenal hormone production. Medications, such as glucocorticoids and hormonal contraceptives, suppress 17-OHP. Document medication use on requisition.

17-OHP in newborn screening

Elevated 17-OHP on newborn screening (heel-stick dried blood spot) is the primary marker for CAH in neonates. Screening cutoffs vary by state, typically 30-60 ng/dL depending on assay and birth weight, and are optimized to detect classic CAH while minimizing false positives. Transiently elevated 17-OHP is common in sick neonates, low-birth-weight infants, and premature babies. Confirmatory testing, including serum 17-OHP, ACTH, cortisol, and electrolytes, is always performed before diagnosis.

Diagnosis of neonatal CAH initiates immediate glucocorticoid therapy to prevent adrenal crisis and reduce virilization exposure in affected females. Digital client records ensure tracking of confirmatory test dates and treatment initiation timelines, critical for compliance documentation.

17-Hydroxyprogesterone and fertility

17-OHP monitoring is integral to fertility assessment and treatment in reproductive medicine. Non-classic CAH, detected via elevated 17-OHP, impairs fertility through irregular ovulation, elevated androgens, and abnormal endometrial development. Screening for non-classic CAH is recommended in women with infertility and hirsutism, as glucocorticoid treatment can restore ovulatory cycles.

In fertility treatment cycles, 17-OHP is sometimes measured during baseline assessment to stratify risk for poor ovarian response. Practitioners order the test during follicular phase before cycle initiation to establish baseline adrenal and ovarian steroid function.

How to order this test: Quick reference for clinicians

Document the following on the requisition to ensure accurate lab interpretation and reference range selection:

• Patient age and sex
• Menstrual cycle phase, if female
• Current medications, especially glucocorticoids and oral contraceptives
• Clinical indication, such as CAH screening, PCOS evaluation, or hirsutism workup
• Any recent illness

Conclusion

The 17-hydroxyprogesterone test is essential for diagnosing and monitoring adrenal disorders, CAH, PCOS, and fertility issues. Understanding reference ranges, collection timing, and result interpretation ensures clinically appropriate ordering and patient care. Download the template above to keep this reference at hand during clinical workflows and patient consultations.

Continue your research

Monitoring ovarian response during fertility treatment? Doppler ultrasound report template documents imaging findings alongside hormone results.

Coordinating care for patients with concurrent endocrine conditions? Diabetes nursing care plan template keeps metabolic monitoring organized alongside hormone panels.

Tracking long-term wellbeing in CAH or PCOS management? Quality of life assessment template gives a structured way to monitor patient-reported outcomes.

Frequently asked questions